Evaluating a Novel Collaboration Between NOTCH1 and MLL1 for Improved Targeted Treatments in T-ALL

The Mark Foundation for Cancer Research-Leukemia & Lymphoma Society Fellow (2021-Present)

Therese Vu, PhD, University of Colorado Denver

Therese Vu, PhD

Dr. Vu has been awarded a grant supporting her work to develop combination therapies to treat patients with T-cell acute lymphoblastic leukemia (T-ALL), a disease with a very poor prognosis. She is testing inhibitors targeting both the so-called mixed lineage leukemia 1 (MLL1) protein and the NOTCH1 protein, to weaken T-ALL cells and make them more susceptible to treatment.

Content courtesy of Leukemia & Lymphoma Society


Straube J, Lane SW, Vu T. Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes. Bioessays. 2021.

Straube J, Eifert T, Vu T, Janardhanan Y, Haldar R, von Eyss B, Cooper L, Bruedigam C, Ling VY, Cooper E, Patch AM, Bullinger L, Schnoeder TM, Bywater M, Heidel FH, Lane SW. Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia. Leukemia. 2023.